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1. Introduction
At the beginning of the 19th century, Carrel and Leriche developed
the techniques of vascular anastomoses, laying the foundations
for the very existence of our discipline. 1 In 1948, in Lisbon,
Monitz performed the ﬁrst femoral endarterectomy (under local
anesthesia); 2 in the same period, in Paris, Kunlin performed the
ﬁrst reversed saphenous vein femoro-popliteal bypass. 3 Two years
later, thanks to the French experience, the boundaries moved even
further, when Oudot 4 performed the ﬁrst bypass for occlusive
aortic disease and when, in 1954, we saw the ﬁrst intervention for
abdominal aortic aneurysm byDubost; 5 the patient died after 8 years
because of myocardial infarction. A milestone was the ﬁrst carotid
endarterectomy by Eastcott (London, 1954); 6 although not the ﬁrst
endarterectomyperformed, itwas theﬁrst to appear in the literature.
All these surgeons have created our discipline. They have invented
the tools toworkwith and, especially, were the ﬁrst to understand the
natural course of vascular disease.
We maintained that brand of leadership until the early 1990s. Our
ability and devotion to work hard were the reasons for our success.
Looking back over our shoulders, we must admit, however, that our
discipline has not changed that much; surely the surgical tools and
the medical outcomes of our patients have improved, but not so the
techniques at our disposal.
At the beginning of the 1990s, a revolution occurred: endovascular
techniques rapidly began to spread. The endovascular revolution
has radically changed our discipline; in this paper we will try to
summarize what has changed in clinical practice.
2. Carotid artery
Carotid artery stenting (CAS) has emerged as a useful, potentially
less invasive alternative to carotid endarterectomy (CEA) but contro-
versy presently surrounds this procedure. 7,8 During the last decade
there have been important innovations in the device, technical
reﬁnements and a better knowledge of patient selection. With the
introduction of CAS, vascular surgeons have been challenged to
change their point of view inmanaging severe carotid artery stenosis.
Several trials have suggested equivalent results for CAS and CEA. 9–12
Long-awaited results from the CREST (Carotid Revascularization
Endarterectomy versus Stenting Trial) study have recently been
presented 13 and shed a new light on CEA versus CAS as a critical
issue (Fig. 1). CREST compared CAS to CEA for the treatment of carotid
Fig. 1. Intraoperative images of (A) CEA and (B) CAS.
artery stenosis to prevent stroke in symptomatic and asymptomatic
patients. More than 2500 patients were enrolled from more than
100 centers in North America and Canada over a 9-year period.
The occurrence of the composite primary end-point of any stroke,
myocardial infarction, or death during the periprocedural period
or ipsilateral stroke on follow-up, was not signiﬁcantly different
between the CEA and CAS groups: stenting 7.2%, surgery 6.8%. The
overall safety and efﬁcacy of the two procedures was largely the same
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with equal beneﬁts for both men and women, and for patients with
and without previous neurological symptoms. However, there were
more heart attacks (2.3%) in the surgical group compared to 1.1% in the
stenting group, and more strokes in the stenting group (4.1%) versus
2.3% for the surgical group in the weeks following the procedure.
In particular, few strokes were disabling; the rate of non-disabling
stroke was 2.7% for CAS vs. 1.4% for CEA, and the rate of disabling
stroke was 1.4% for CAS vs. 0.8% for CEA, without achieving statistical
signiﬁcance.
These results did not aim to establish whether stenting or
endarterectomy will win the race, but more likely how these two
procedures could be selectively and properly applied to individual
patients. Depending on patient’s characteristics, one proceduremight
have an advantage over the other. Recent results allowed experienced
operators in both techniques to adapt a treatment strategy tailored to
each patient. In this regard, only specialistswho can offer both options
of treatment will offer the greatest beneﬁt for the patient.
3. Aorta
Open surgical repair of lesions of the descending thoracic aorta has
been the “state-of-the-art” treatment for many decades.
However, in specialized vascular centers, thoracic endovascular
aortic repair and hybrid aortic procedures have been implemented as
novel treatment options. The current clinical results show that these
procedures can be performedwith lowmorbidity andmortality rates.
However, due to a lack of randomized trials, the level of reliability
of these new treatment modalities remains a matter of discussion.
Clinical decision-making is generally based on the experience of the
vascular center aswell as on individual factors, such as life expectancy,
comorbidity, aneurysm aetiology, aortic diameter and morphology.
Endovascular aneurysm repair (EVAR) is aminimally invasive surgery
for the treatment of aortic aneurisms based on the use of a
stent graft, usually deployed inside the aneurysm through femoral
access to exclude the sac from the circulation. EVAR requires adequate
ﬁxation sites for effective sealing and ﬁxation. These requirements
should be carefully assessed and veriﬁed prior to surgery with
adequate imaging to select suitable patients for endografting (Fig. 2).
Fig. 2. Endovascular treatment of an abdominal aortic aneurism.
Potential advantages of EVARover open repair (OR) include reduced
operative time, avoidance of general anesthesia, less trauma and post-
operative pain, reduced hospital length of stay and less need for
intensive care unit (ICU), reduced blood loss and reduced immediate
postoperative mortality. Potential disadvantages include the risk of
incomplete aneurysm sealing, with the development of continuous
reﬁlling of the aneurysm sac, either because the graft does not seal
completely at the extremities (Type I endoleak), between segments
(Type III endoleak), or because of backﬁlling of the aneurysm from
other small vessels in the aneurysm wall (Type II endoleak).
Thoracic endovascular aortic repair (TEVAR) has been proposed
to be a less invasive treatment for treatment of thoracic aortic
aneurysms. Early clinical results with thoracic aortic stent grafts have
shown signiﬁcantly improved early quality of life versus open surgery
andhave generally showna trend toward better perioperative survival
and freedom from major complications. 14–17 The original Food and
Drug Administration Investigational Device Exemption (FDA IDE)
studies that led to approval of the currently available devices,
including the Gore TAG (W.L. Gore & Associates, Inc, Flagstaff, AZ),
Medtronic Talent (Medtronic, Inc, Minneapolis, MI), and Cook Zenith
TX2 stent grafts (Cook Endovascular, Bloomington, IN), speciﬁcally
looked at patients with favorable anatomy in descending thoracic
aortic aneurysms. The early results in these trials were highly
favorable toward stent grafts.
Open repair of the thoracic aorta is traditionally associated
with signiﬁcant permanent neurologic morbidity and mortality. In
recent series from high-volume centers of excellence, mortality and
neurologic morbidity rates range from 5.4% to 7.2% for mortality,
2.1% to 6.2% for permanent stroke, 5.7% for permanent paraparesis,
and 0.8% to 2.3% for permanent paralysis, respectively. 18,19 In the
multicenter open control groups for the Gore TAG, Medtronic Talent,
and Cook Zenith TX2 stent grafts, mortality and neurologic morbidity
rates range from 5.7% to 11.7% for mortality, 4.3% to 8.6% for
permanent stroke, 5.7% for permanent paraparesis, and 3.4% to 8.5%
for permanent paralysis, respectively. Similarly, the perioperative
results for the 3 stent graft trials in the TEVAR arms showed
1.9% to 2.1% for mortality, 2.4% to 4% for stroke, 4.4% to 7.2% for
permanent paraparesis, and 1.3% to 3% for permanent paralysis,
respectively. 20–22
Randomized controlled trials, large registries and single-center se-
ries comparing EVARwith OR have shown that theminimally invasive
approach has lower early morbidity andmortality with low incidence
of primary conversion to OR after EVAR, between 0.9% and 5.9%. 23–28
The DREAM trial reported an operative mortality rate of 4.6% in the
open repair group and 1.2% in the endovascular repair group, with
a higher rate of moderate and severe systemic complications in the
open surgical arm. However, cardiac complication rate in this trialwas
similar in the two groups (5.7% for OR vs 5.3% for EVAR), underlining
that even EVAR should be considered a procedure with intermediate
to high risk of cardiac complications. 29
The increased use of EVAR has been affected by limitations of
the related technology, although the percentage of abdominal aortic
aneurysms (AAA) deemed suitable for EVAR has been growing over
the past decade, due to improvements in graft design. However, long-
term durability is still being questioned especially in case of adverse
anatomy, rendering the pre-operative anatomical evaluation crucial
for late success of EVAR.
Recent experience demonstrates that treatment with new-genera-
tion devices is technically feasible and safe, yielding satisfactory
results even in challenging aortic anatomies. The duration of proce-
dures, intraoperative contrast use and radiation exposure time are
similar compared with treatment of standard anatomies, indirectly
demonstrating an absence of additional intraoperative difﬁculties.
The particular characteristics of this device seem to make it
appropriate for the treatment of highly angulated and short necks,
especially in patients at high surgical risk. The clinical signiﬁcance
is to demonstrate the effectiveness of the new devices even in the
case of difﬁcult anatomies, as well as its postoperative safeness in the
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case of off-label indications in patients otherwise considered unﬁt for
surgery. 30
Experience with endovascular exclusion of aneurysms in the chest
and abdomen has facilitated the extension of this technology into the
treatment of aortic dissection. Endovascular repair of the ascending
aorta is not indicated due to limitations of current technology in
dealing with the dynamic nature of the ascending aorta and aortic
arch. Furthermore, the proximity to and potential for involvement
of the coronary arteries and aortic valve in acute type A dissection
cannot be dealt with by current technology. Endovascular exclusion
of the descending thoracic aorta in type A dissection is gaining
traction. Endovascular repair of the descending thoracic aorta has
also emerged as an advantageous alternative to traditional surgical
techniques in the management of appropriate cases of acute com-
plicated type B aortic dissection. The ultimate goal of open surgical
and endovascular treatment of acute aortic dissections is restoration
of ﬂow through the true lumen, exclusion of the primary entry tears
with the potential for facilitating aortic remodeling, and prevention
of potential aneurysmal degeneration. TEVAR has become a preferred
therapeutic option for a wide spectrum of aortic pathologies in
both the elective and emergent settings. 31–36 Conventional open
surgical repair of type B dissection is becoming less common due
to the high perioperative morbidity and mortality. The availability
of a highly experienced multidisciplinary team is essential because
these patients are frequently in critical condition. 37,38 Recently, the
Society for Vascular Surgery Outcomes Committee in conjunction
with ad hoc members from the American Association for Thoracic
Surgery, Society of Thoracic Surgeons, and Society for Interventional
Radiology reported 1-year outcomes in patients with chronic Type B
aortic dissections treated with TEVAR who presented with rupture
or malperfusion with acute (<14 days), subacute (15–30 days), or
chronic (31–90 days) symptom onset until required intervention.
These 85 patientswere consolidated from5 centers of excellencewith
single-center FDA IDE to establish a 30-day mortality with 1-year
follow-up. The actuarial mortality estimates observed were 10.8% at
30 days and 29.4% at 1 year. 39 This represents a signiﬁcantly lower
percentage when compared with the older reports of open thoracic
aortic surgical repair with 24–35% mortality at 30 days. 40
4. Lower limb
The most important revolution in treatment of critical limb is-
chemia (CLI) is represented by the “new horizons” in the treatment
of chronic total occlusion (CTO) in the infrainguinal arteries.
Subintimal angioplasty (SIA) is a minimally invasive percutaneous
technique for the recanalization of occluded iliac and infrainguinal
arteries. 41–43 First described by Bolia et al. 44 in 1989, this technique
has been used increasingly as an alternative to lower limb bypass
procedures in CLI. 45 It is usually performed under local anesthesia
and is based on the creation of a subintimal channel by endoluminal
dissection and angioplasty. This minimally invasive technique is well
tolerated by most patients and requires only a modest amount of
equipment. 46 Success with SIA has been enhanced by the introduc-
tion of re-entry devices to facilitate recanalization. 47 The advantages
of a percutaneous interventional procedure over bypass surgery are
briefer anesthesia, no incision in an ischemic leg, and fewer healing
complications, as well as less systemic stress (local anesthesia),
faster recovery, and earlier ambulation. Moreover, failed SIA does not
preclude the possibility of surgical revascularization. 48 Further, redo
percutaneous procedures might be more readily done than repeat
surgery, with the possibility of offering future surgical intervention
if needed. The procedure, however, needs to be performed by a
skilled team of trained operators. Generally, antegrade ipsilateral
percutaneous femoral access is preferred when at least 5 cm of a
patent proximal segment of the superﬁcial femoral artery (SFA) is
evident at ultrasonography. A contralateral approach via a crossover
long sheath is used only in the presence of SFA occlusion in its origin,
high femoral bifurcation (documented by ultrasound), or obesity.
A soft, angled hydrophilic 0.035-inch guidewire in combination with
a 5-F angled hydrophilic catheter is brought near the origin of the
occlusion. An attempt to advance the guidewire through the true
lumen is done in all cases. When needed, the subintimal plane is
entered by forming a loop at the end of the guidewire and advancing
it, along with the catheter, across the occluded arterial segment.
Indicators of subintimal dissection include characteristic resistance
to wire advancement, a broad helical path taken by the wire during
advancement, the guidewire loop adapting to the width of the native
vessel, and a subtle release of wire resistance with true lumen re-
entry near the distal portion of the arterial occlusion. Following
conﬁrmation of catheter re-entry into the true lumen, balloon
angioplasty is used to dilate the subintimal channel. A re-entry device
is used only when recanalization by simple SIA is unsuccessful.
Stenting is performed only if there is residual stenosis >30% or a ﬂow-
limiting dissection. Most physicians use a standardized approach:
a brief SIA procedure of 30–40 minutes and application of a re-entry
device only when accessing the true lumen is difﬁcult, so as not to
dissect the popliteal artery or threaten the supragenicular collaterals.
If the procedure cannot be concluded safely, suggestion is to continue
the intervention surgically or use a hybrid approach. The presence
of a vascular surgeon in the team is important inasmuch as the ﬁrst
intervention should not preclude the possibility of further surgical
revascularization. 49
In the last year, in the world of Vascular surgery, the “diabetic
foot revolution” has begun. 50 Diabetes is a chronic disease that
involves 350million peopleworldwide, a number thatwill increase to
440million by 2030. 51,52 Every year, 1million people undergo a lower
limb amputation as a consequence of diabetes. It is hard to believe
that, although 85% of all amputations are preceded by foot ulcers, the
prevalence of amputations ranges from 0.2% to 4.8%, with an annual
incidence of 46.1 to 936 per 100,000. According to Prompers et al., 53
the presence of arterial obstructive disease greatly increases the risk
of amputation, but diabetic sensory motor neuropathy increases only
the risk of ulcers; foot infection, which frequently complicates the
clinical course of ulcerative lesions of the foot, raises the risk of
amputation only if associated with CLI. It is well known that all
the complications associated with the diabetic foot are complex and
costly, 54,55 so we must know what to do in this particular subgroup
of patients.
Caravaggi 56 recently reported a well-designed triage protocol for
patients with diabetic foot. According to this protocol, the presence
of an infectious process indicates a need for urgent treatment.
Unfortunately, the literature contains scant data on which is the best
treatment option with respect to the degree of ischemia and the
infection. However, we suggest that early and aggressive debridement
of the infectionmust always precede the revascularization procedure.
This approach is also recommended by most recent guidelines, par-
ticularly the International Guidelines on Diabetic Foot Treatment 57
and the European Society of Vascular Surgery guidelines on CLI and
diabetic foot. 58 Nonetheless, only a few centers apply this complex
and integrated approach, which implies that the dramatic delay in the
diagnosis and treatment of diabetic footwill increase not only the risk
of major amputation but also of death. We strongly suggest a 4-step
approach to patients with diabetic foot:
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Fig. 3. Pre- and post-operative angiogram of a lower limb revascularization.
1. Early diagnosis with a 24-hour on-call diabetic foot team; all the
members of the team should be able to perform a duplex scan and
to identify an infectious disease, if present.
2. Urgent treatment of severe foot infection with aggressive surgical
debridement performed by highly skilled operators in the operat-
ing theater.
3. Revascularization (Fig. 3) with a straight ﬂow to the foot. In all
cases, the ﬁrst-line approach should be endovascular (angioplasty ±
stenting).
4. Deﬁnitive treatment: wound healing, reconstructive surgery, and
orthesis.
This protocol requires highly skilled professionals working together
around the clock toward the goal of avoiding major amputations
in patients with diabetic foot. It is a challenging and complex task,
but only an integrated, interdisciplinary diabetic foot team can
signiﬁcantly impact the outcome of our patients.
5. Conclusions
Wemust be ‘master surgeons’, capable ofworkingwith the same skills
in both traditional and endovascular surgical procedures; butwemust
also be ‘master physicians’, who are entirely managing their patients.
We believe this deﬁnition is crucial: only those surgeons with these
requirements can be deﬁned as vascular surgeons.
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